Showing results (251-260 of 288) with videos related to
Sort By:
Pageof 29
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.The Lancet. Oncology|January 19, 2020
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialMichael R Migden, Nikhil I Khushalani, Anne Lynn S Chang, et al.Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.Annals of Medicine and Surgery (2012)|June 8, 2026
Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort studyEden Mane, Mark Tacey, Ben Loveday, et al.Journal for Immunotherapy of Cancer|August 20, 2021
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisDanny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, et al.Cancer|April 24, 2026
Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignanciesTae Min Kim, Stephen K Williamson, Kyriakos P Papadopoulos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.BMC Cancer|December 17, 2022
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Swetha Sridharan, James Lynam, et al.European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.Pageof 29